161 related articles for article (PubMed ID: 37958656)
1. Down-Regulation of CYP3A4 by the K
Ohya S; Kajikuri J; Kito H; Matsui M
Int J Mol Sci; 2023 Oct; 24(21):. PubMed ID: 37958656
[TBL] [Abstract][Full Text] [Related]
2. K
Ohya S; Kajikuri J; Endo K; Kito H; Matsui M
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948357
[TBL] [Abstract][Full Text] [Related]
3. Ca
Ohya S; Kajikuri J; Endo K; Kito H; Elboray EE; Suzuki T
Cancer Sci; 2021 Sep; 112(9):3769-3783. PubMed ID: 34181803
[TBL] [Abstract][Full Text] [Related]
4. [Overcoming chemoresistance by Ca
Ohya S
Nihon Yakurigaku Zasshi; 2023; 158(6):478-482. PubMed ID: 37914328
[TBL] [Abstract][Full Text] [Related]
5. The Complex Dynamic of Phase I Drug Metabolism in the Early Stages of Doxorubicin Resistance in Breast Cancer Cells.
Barata IS; Gomes BC; Rodrigues AS; Rueff J; Kranendonk M; Esteves F
Genes (Basel); 2022 Oct; 13(11):. PubMed ID: 36360213
[TBL] [Abstract][Full Text] [Related]
6. Chrysin enhances sensitivity of BEL-7402/ADM cells to doxorubicin by suppressing PI3K/Akt/Nrf2 and ERK/Nrf2 pathway.
Gao AM; Ke ZP; Shi F; Sun GC; Chen H
Chem Biol Interact; 2013 Oct; 206(1):100-8. PubMed ID: 23994249
[TBL] [Abstract][Full Text] [Related]
7. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
8. Apigenin sensitizes doxorubicin-resistant hepatocellular carcinoma BEL-7402/ADM cells to doxorubicin via inhibiting PI3K/Akt/Nrf2 pathway.
Gao AM; Ke ZP; Wang JN; Yang JY; Chen SY; Chen H
Carcinogenesis; 2013 Aug; 34(8):1806-14. PubMed ID: 23563091
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow niche chemoprotection of metastatic solid tumors mediated by CYP3A4.
Ghiaur G; Valkenburg KC; Esteb C; Ambinder A; Imus PH; Pienta KJ; Jones RJ
Cancer; 2023 Jun; 129(11):1744-1751. PubMed ID: 36840972
[TBL] [Abstract][Full Text] [Related]
10. Drug resistance associates with activation of Nrf2 in MCF-7/DOX cells, and wogonin reverses it by down-regulating Nrf2-mediated cellular defense response.
Zhong Y; Zhang F; Sun Z; Zhou W; Li ZY; You QD; Guo QL; Hu R
Mol Carcinog; 2013 Oct; 52(10):824-34. PubMed ID: 22593043
[TBL] [Abstract][Full Text] [Related]
11. Down-regulation of human CYP3A4 by the inflammatory signal interleukin-6: molecular mechanism and transcription factors involved.
Jover R; Bort R; Gómez-Lechón MJ; Castell JV
FASEB J; 2002 Nov; 16(13):1799-801. PubMed ID: 12354697
[TBL] [Abstract][Full Text] [Related]
12. Combining GRP78 suppression and MK2206-induced Akt inhibition decreases doxorubicin-induced P-glycoprotein expression and mitigates chemoresistance in human osteosarcoma.
Xia YZ; Yang L; Xue GM; Zhang C; Guo C; Yang YW; Li SS; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 Aug; 7(35):56371-56382. PubMed ID: 27486760
[TBL] [Abstract][Full Text] [Related]
13. Clinically Relevant Cytochrome P450 3A4 Induction Mechanisms and Drug Screening in Three-Dimensional Spheroid Cultures of Primary Human Hepatocytes.
Hendriks DFG; Vorrink SU; Smutny T; Sim SC; Nordling Å; Ullah S; Kumondai M; Jones BC; Johansson I; Andersson TB; Lauschke VM; Ingelman-Sundberg M
Clin Pharmacol Ther; 2020 Oct; 108(4):844-855. PubMed ID: 32320483
[TBL] [Abstract][Full Text] [Related]
14. DJ-1 is involved in the multidrug resistance of SGC7901 gastric cancer cells through PTEN/PI3K/Akt/Nrf2 pathway.
Qiu L; Ma Z; Li X; Deng Y; Duan G; Zhao LE; Xu X; Xiao L; Liu H; Zhu Z; Chen H
Acta Biochim Biophys Sin (Shanghai); 2020 Dec; 52(11):1202-1214. PubMed ID: 33079995
[TBL] [Abstract][Full Text] [Related]
15. Lgr5-mediated p53 Repression through PDCD5 leads to doxorubicin resistance in Hepatocellular Carcinoma.
Ma Z; Guo D; Wang Q; Liu P; Xiao Y; Wu P; Wang Y; Chen B; Liu Z; Liu Q
Theranostics; 2019; 9(10):2967-2983. PubMed ID: 31244936
[TBL] [Abstract][Full Text] [Related]
16. Down-Regulation of Ca
Khatun A; Fujimoto M; Kito H; Niwa S; Suzuki T; Ohya S
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27973439
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-760 Inhibits Doxorubicin Resistance in Hepatocellular Carcinoma through Regulating Notch1/Hes1-PTEN/Akt Signaling Pathway.
Tian T; Fu X; Lu J; Ruan Z; Nan K; Yao Y; Yang Y
J Biochem Mol Toxicol; 2018 Aug; 32(8):e22167. PubMed ID: 29968951
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA-132 and microRNA-212 mediate doxorubicin resistance by down-regulating the PTEN-AKT/NF-κB signaling pathway in breast cancer.
Xie M; Fu Z; Cao J; Liu Y; Wu J; Li Q; Chen Y
Biomed Pharmacother; 2018 Jun; 102():286-294. PubMed ID: 29567542
[TBL] [Abstract][Full Text] [Related]
19. Roles of CYP3A4, CYP3A5 and CYP2C8 drug-metabolizing enzymes in cellular cytostatic resistance.
Hofman J; Vagiannis D; Chen S; Guo L
Chem Biol Interact; 2021 May; 340():109448. PubMed ID: 33775687
[TBL] [Abstract][Full Text] [Related]
20. Amplified in breast cancer 1 enhances human cholangiocarcinoma growth and chemoresistance by simultaneous activation of Akt and Nrf2 pathways.
Chen Q; Li W; Wan Y; Xia X; Wu Q; Chen Y; Lai Z; Yu C; Li W
Hepatology; 2012 Jun; 55(6):1820-9. PubMed ID: 22213475
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
